Arnold G. Vulto

12.6k total citations · 2 hit papers
227 papers, 7.9k citations indexed

About

Arnold G. Vulto is a scholar working on Economics and Econometrics, Immunology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Arnold G. Vulto has authored 227 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Economics and Econometrics, 68 papers in Immunology and 45 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Arnold G. Vulto's work include Pharmaceutical Economics and Policy (64 papers), Biosimilars and Bioanalytical Methods (64 papers) and Health Systems, Economic Evaluations, Quality of Life (50 papers). Arnold G. Vulto is often cited by papers focused on Pharmaceutical Economics and Policy (64 papers), Biosimilars and Bioanalytical Methods (64 papers) and Health Systems, Economic Evaluations, Quality of Life (50 papers). Arnold G. Vulto collaborates with scholars based in Netherlands, Belgium and United States. Arnold G. Vulto's co-authors include Steven Simoens, J. Aarts, Maarten J. ten Berg, Teun van Gelder, Isabelle Huys, Pieter Dylst, Loes E. Visser, Ron A. A. Mathôt, Albert Hofman and Liese Barbier and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nature Biotechnology and PEDIATRICS.

In The Last Decade

Arnold G. Vulto

223 papers receiving 7.6k citations

Hit Papers

Overriding of Drug Safety Alerts in Computerized Physicia... 2005 2026 2012 2019 2005 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Overriding of Drug Safety Alerts in Computerized Physician Order Entry
    2005 847 citations Arnold G. Vulto et al. profile →
  2. Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
    2013 561 citations C. B. H. W. Lamers, Arnold G. Vulto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arnold G. Vulto Netherlands 47 1.5k 1.2k 1.2k 1.1k 1.1k 227 7.9k
Sean Hennessy United States 50 621 0.4× 732 0.6× 567 0.5× 342 0.3× 678 0.6× 268 8.7k
Miriam Sturkenboom Netherlands 68 482 0.3× 1.4k 1.1× 1.7k 1.5× 692 0.6× 525 0.5× 461 18.0k
Jeffrey K Aronson United Kingdom 47 371 0.2× 1.4k 1.1× 1.8k 1.5× 909 0.8× 445 0.4× 327 11.6k
Walter E. Haefeli Germany 62 497 0.3× 968 0.8× 2.5k 2.1× 1.8k 1.6× 2.6k 2.3× 532 15.3k
Gianluca Trifirò Italy 46 523 0.3× 983 0.8× 986 0.8× 363 0.3× 356 0.3× 270 7.0k
Lars L. Gustafsson Sweden 49 261 0.2× 1.3k 1.1× 1.5k 1.2× 1.7k 1.5× 737 0.7× 247 7.8k
Luis A. Garcı́a Rodrı́guez Spain 65 605 0.4× 682 0.6× 470 0.4× 1.1k 0.9× 1.1k 1.0× 282 15.3k
I. Ralph Edwards Sweden 39 459 0.3× 963 0.8× 1.5k 1.3× 732 0.6× 467 0.4× 158 7.7k
K. Arnold Chan United States 51 350 0.2× 995 0.8× 1.0k 0.9× 331 0.3× 848 0.8× 210 10.4k
Kevin Haynes United States 47 833 0.6× 452 0.4× 440 0.4× 264 0.2× 893 0.8× 195 6.4k

Countries citing papers authored by Arnold G. Vulto

Since Specialization
Citations

This map shows the geographic impact of Arnold G. Vulto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnold G. Vulto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnold G. Vulto more than expected).

Fields of papers citing papers by Arnold G. Vulto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnold G. Vulto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnold G. Vulto. The network helps show where Arnold G. Vulto may publish in the future.

Co-authorship network of co-authors of Arnold G. Vulto

This figure shows the co-authorship network connecting the top 25 collaborators of Arnold G. Vulto. A scholar is included among the top collaborators of Arnold G. Vulto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnold G. Vulto. Arnold G. Vulto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bemt, Bart J. F. van den, Daniel Aletaha, Rieke Alten, et al.. (2023). Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD Open. 9(1). e002898–e002898. 14 indexed citations
2.
3.
Stok, Merel, Arnold G. Vulto, Wendy W. J. Unger, et al.. (2022). Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease. Molecular Therapy — Methods & Clinical Development. 25. 520–532. 12 indexed citations
4.
Vulto, Arnold G., et al.. (2022). Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe. BioDrugs. 36(2). 217–229. 17 indexed citations
5.
Beusechem, Victor W. van, David P. Noske, C. B. H. W. Lamers, et al.. (2022). Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM:A Phase I Clinical Trial Including Correlative Studies. Digital Commons@Becker (Washington University School of Medicine). 67 indexed citations
6.
Zaal, Rianne J., et al.. (2020). Physicians’ acceptance of pharmacists’ interventions in daily hospital practice. International Journal of Clinical Pharmacy. 42(1). 141–149. 39 indexed citations
7.
8.
Moorkens, Evelien, Arnold G. Vulto, & Isabelle Huys. (2020). Biosimilars in Belgium: a proposal for a more competitive market. Acta Clinica Belgica. 76(6). 441–452. 16 indexed citations
9.
Moorkens, Evelien, Arnold G. Vulto, Martin Schulz, et al.. (2020). Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals. 13(10). 324–324. 22 indexed citations
10.
Moorkens, Evelien, et al.. (2020). Economic evaluation of biosimilars for reimbursement purposes – what, when, how?. SHILAP Revista de lepidopterología. 8(1). 1739509–1739509. 9 indexed citations
11.
Moorkens, Evelien, Arnold G. Vulto, & Isabelle Huys. (2020). An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?. mAbs. 12(1). 1743517–1743517. 32 indexed citations
12.
13.
14.
Aerts, Joachim G.J.V., Pauline L. de Goeje, Robin Cornelissen, et al.. (2017). Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. Clinical Cancer Research. 24(4). 766–776. 71 indexed citations
15.
Moorkens, Evelien, et al.. (2016). Market Uptake Models Of Biosimilars And Off-Patent Biological Medicines. Value in Health. 19(7). A452–A452.
16.
Goede, Anna L. de, Arnold G. Vulto, Albert D. M. E. Osterhaus, & Rob A. Gruters. (2014). Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection. Annales Pharmaceutiques Françaises. 73(2). 87–99. 10 indexed citations
17.
Dylst, Pieter, Arnold G. Vulto, & Steven Simoens. (2014). Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability. Expert Review of Pharmacoeconomics & Outcomes Research. 15(1). 33–42. 8 indexed citations
18.
Ahsman, Maurice J., et al.. (2009). Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Archives of Disease in Childhood Fetal & Neonatal. 95(2). F109–F114. 46 indexed citations
19.
Bernard, Bert F., Ananth Srinivasan, Jack L. Erion, et al.. (2007). Five Stabilized 111 In-Labeled Neurotensin Analogs in Nude Mice Bearing HT29 Tumors. Cancer Biotherapy and Radiopharmaceuticals. 22(3). 374–382. 4 indexed citations
20.
Birkenhäger, Tom K., Walter W. van den Broek, P. Moleman, Arnold G. Vulto, & Jan A. Bruijn. (2005). Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?. Psychopharmacology. 181(3). 595–599. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sean Hennessy Breakdown of academic impact, for papers by Miriam Sturkenboom Breakdown of academic impact, for papers by Jeffrey K Aronson Breakdown of academic impact, for papers by Walter E. Haefeli Breakdown of academic impact, for papers by Gianluca Trifirò Breakdown of academic impact, for papers by Lars L. Gustafsson Breakdown of academic impact, for papers by Luis A. Garcı́a Rodrı́guez Breakdown of academic impact, for papers by I. Ralph Edwards Breakdown of academic impact, for papers by K. Arnold Chan Breakdown of academic impact, for papers by Kevin Haynes
Rankless by CCL
2026